Description
best bpc 157 capsules australia BPC-157 + KPV performance Net Weight:40mg 5-Amino-1MQ 5mg NNMT Inhibitor
5-Amino-1MQ 5mg NNMT Inhibitor | Research Australia | GBL
Key characteristics A small molecule (quinolinium derivative), NOT a peptide Acts as an inhibitor of the enzyme NNMT Rationale is preservation of NAD+ / methyl-donor balance in metabolically active tissue Evidence to date is largely preclinical (cell and rodent models) No approved human therapeutic indication Reported research dosing reference only Educational reference, not dosing guidance
performance
Net Weight:40mg
These findings are generally similar to the presentation of the Phase 1 Clinical Trial (42 volunteers) (NCT02637284), which established that the oral self-administration of BPC 157 in doses of 1, 3, 6, or 9 mg per day for as long as two weeks is safe and well-tolerated